Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2019

Global Markets Direct’s, ‘Influenza A Virus, H7N9 Subtype Infections – Pipeline Review, H2 2019’, provides an overview of the Influenza A Virus, H7N9 Subtype Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections

– The report reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Influenza A Virus, H7N9 Subtype Infections therapeutics and enlists all their major and minor projects

– The report assesses Influenza A Virus, H7N9 Subtype Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AIM ImmunoTech Inc

AusBio Ltd

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

Codagenix Inc

CSL Ltd

EpiVax Inc

Genentech Inc

Greffex Inc

Hualan Biological Bacterin Co Ltd

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Moderna Therapeutics Inc

NanoViricides Inc

New Amsterdam Sciences Inc

Ology Bioservices Inc

Pneumagen Ltd

Sanofi Pasteur SA

Seqirus Ltd

Shanghai Institute of Biological Products Co Ltd

Shionogi & Co Ltd

Virion Biotherapeutics

Visterra Inc

Vivaldi Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Influenza A Virus, H7N9 Subtype Infections Overview

Influenza A Virus, H7N9 Subtype Infections Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Influenza A Virus, H7N9 Subtype Infections Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Influenza A Virus, H7N9 Subtype Infections Companies Involved in Therapeutics Development

AusBio Ltd

Beijing Minhai Biotechnology Co Ltd

Cocrystal Pharma Inc

EpiVax Inc

Genentech Inc

iBio Inc

Inovio Pharmaceuticals Inc

Medicago Inc

Medigen Vaccine Biologics Corp

Moderna Therapeutics Inc

NanoViricides Inc

Ology Bioservices Inc

Sanofi Pasteur SA

Shionogi & Co Ltd

VirionHealth Ltd

Visterra Inc

Vivaldi Biosciences Inc

Influenza A Virus, H7N9 Subtype Infections Drug Profiles

AT-501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baloxavir marboxil Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-42344 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine 1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (monovalent) vaccine 2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (split virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (whole virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] (whole virion) vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza [strain A/H7N9] vaccine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MD-2009 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mRNA-1851 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-7529 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NVINF-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Neuraminidase A for Infectious Diseases Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-126LAIV Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VH-244 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-410 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Influenza A Virus, H7N9 Subtype Infections Dormant Projects

Influenza A Virus, H7N9 Subtype Infections Product Development Milestones

Featured News & Press Releases

Sep 08, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 6th European Scientific Working Group in Influenza Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AIM ImmunoTech Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by AusBio Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Cocrystal Pharma Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Codagenix Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by CSL Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by EpiVax Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Genentech Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Greffex Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Hualan Biological Bacterin Co Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medicago Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Medigen Vaccine Biologics Corp, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Moderna Therapeutics Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by NanoViricides Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by New Amsterdam Sciences Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Ology Bioservices Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Pneumagen Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Sanofi Pasteur SA, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Seqirus Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Shanghai Institute of Biological Products Co Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Shionogi & Co Ltd, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Virion Biotherapeutics, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Visterra Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Pipeline by Vivaldi Biosciences Inc, H2 2019

Influenza A Virus, H7N9 Subtype Infections – Dormant Projects, H2 2019

List of Figures

List of Figures

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports